 Paul Maroni
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2024 | 1058 | 3.730 |
Why?
| | Prostatectomy | 8 | 2019 | 102 | 1.480 |
Why?
| | Testicular Neoplasms | 7 | 2023 | 115 | 1.080 |
Why?
| | Urology | 3 | 2020 | 63 | 0.830 |
Why?
| | Embolism | 1 | 2021 | 46 | 0.680 |
Why?
| | Urethra | 1 | 2021 | 56 | 0.680 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 78 | 0.670 |
Why?
| | Androgen Antagonists | 4 | 2024 | 92 | 0.670 |
Why?
| | Laser Therapy | 1 | 2021 | 131 | 0.610 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1044 | 0.460 |
Why?
| | Kidney Medulla | 2 | 2005 | 31 | 0.450 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 445 | 0.400 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 439 | 0.360 |
Why?
| | Urination Disorders | 1 | 2011 | 14 | 0.350 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 166 | 0.350 |
Why?
| | Male | 56 | 2024 | 71659 | 0.330 |
Why?
| | Prostate | 7 | 2023 | 173 | 0.320 |
Why?
| | Oxalates | 2 | 2008 | 11 | 0.300 |
Why?
| | Neoplasm Grading | 5 | 2021 | 312 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1674 | 0.270 |
Why?
| | Adenocarcinoma | 3 | 2022 | 912 | 0.260 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 217 | 0.260 |
Why?
| | Humans | 59 | 2024 | 143806 | 0.250 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1418 | 0.240 |
Why?
| | Kidney Tubules, Collecting | 1 | 2005 | 27 | 0.230 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.220 |
Why?
| | Brachytherapy | 2 | 2016 | 131 | 0.220 |
Why?
| | Clinical Competence | 1 | 2012 | 1237 | 0.210 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 261 | 0.200 |
Why?
| | Androgens | 4 | 2024 | 194 | 0.190 |
Why?
| | Paraganglioma | 1 | 2022 | 53 | 0.180 |
Why?
| | Cell Hypoxia | 2 | 2015 | 241 | 0.180 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2022 | 90 | 0.180 |
Why?
| | Prolactin | 3 | 1997 | 92 | 0.170 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 116 | 0.170 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 1997 | 45 | 0.170 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 6033 | 0.160 |
Why?
| | Orchiectomy | 3 | 2016 | 76 | 0.160 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2020 | 27 | 0.160 |
Why?
| | Aged | 21 | 2021 | 25356 | 0.160 |
Why?
| | Risk Assessment | 4 | 2020 | 3582 | 0.160 |
Why?
| | Middle Aged | 20 | 2021 | 35398 | 0.150 |
Why?
| | Salvage Therapy | 2 | 2018 | 159 | 0.150 |
Why?
| | Proanthocyanidins | 1 | 2019 | 9 | 0.150 |
Why?
| | Biflavonoids | 1 | 2019 | 9 | 0.150 |
Why?
| | Stromal Cells | 1 | 2019 | 128 | 0.150 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.150 |
Why?
| | Hospitals | 2 | 2023 | 691 | 0.150 |
Why?
| | Catechin | 1 | 2019 | 25 | 0.150 |
Why?
| | Anthocyanins | 1 | 2019 | 35 | 0.140 |
Why?
| | Grape Seed Extract | 1 | 2019 | 43 | 0.140 |
Why?
| | Nomograms | 1 | 2019 | 58 | 0.140 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 11 | 0.140 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2018 | 34 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 1997 | 441 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1103 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 196 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 132 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 200 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 14 | 0.130 |
Why?
| | Biopsy, Needle | 2 | 2016 | 190 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 21 | 0.130 |
Why?
| | Surgical Wound Infection | 2 | 2019 | 328 | 0.130 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.130 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 682 | 0.120 |
Why?
| | Plant Extracts | 1 | 2018 | 212 | 0.120 |
Why?
| | Radiology | 1 | 2019 | 173 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2016 | 92 | 0.120 |
Why?
| | Liver | 4 | 1997 | 1869 | 0.120 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.120 |
Why?
| | Medical Oncology | 1 | 2019 | 332 | 0.120 |
Why?
| | Prognosis | 7 | 2019 | 4162 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 73 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 2 | 1997 | 626 | 0.110 |
Why?
| | Risk | 2 | 2015 | 906 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 328 | 0.110 |
Why?
| | HSP70 Heat-Shock Proteins | 2 | 2008 | 74 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 414 | 0.110 |
Why?
| | Biopsy | 4 | 2023 | 1083 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 151 | 0.110 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.110 |
Why?
| | Genomics | 1 | 2019 | 832 | 0.110 |
Why?
| | Cause of Death | 1 | 2016 | 461 | 0.100 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 20 | 0.100 |
Why?
| | Priapism | 1 | 2013 | 11 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Optics and Photonics | 1 | 2014 | 42 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1261 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 165 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 517 | 0.100 |
Why?
| | Proline | 1 | 2013 | 80 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 162 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2010 | 138 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2018 | 11389 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2016 | 520 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 407 | 0.090 |
Why?
| | Telephone | 1 | 2013 | 181 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2114 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 36 | 0.090 |
Why?
| | Signal Transduction | 4 | 2004 | 5220 | 0.090 |
Why?
| | Survival Rate | 4 | 2017 | 2008 | 0.090 |
Why?
| | Cell Line | 3 | 2008 | 2899 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2014 | 499 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 41 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 80 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 183 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2011 | 74 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1207 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2010 | 56 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2008 | 1129 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1254 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1332 | 0.080 |
Why?
| | Oxygen | 1 | 2015 | 998 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1042 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2022 | 233 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2020 | 8077 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2009 | 273 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 151 | 0.080 |
Why?
| | Counseling | 1 | 2013 | 399 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 962 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 230 | 0.080 |
Why?
| | Lymph Node Excision | 2 | 2014 | 170 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2019 | 2902 | 0.080 |
Why?
| | Survivors | 1 | 2013 | 505 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 22 | 0.070 |
Why?
| | Cystitis | 1 | 2009 | 23 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 37 | 0.070 |
Why?
| | Age Factors | 4 | 2017 | 3330 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 2108 | 0.070 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 41 | 0.070 |
Why?
| | Patient Selection | 2 | 2018 | 692 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 783 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1294 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1465 | 0.070 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3615 | 0.060 |
Why?
| | Image-Guided Biopsy | 2 | 2020 | 42 | 0.060 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 128 | 0.060 |
Why?
| | Societies, Medical | 1 | 2011 | 874 | 0.060 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 173 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 167 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 296 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2008 | 388 | 0.060 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 333 | 0.060 |
Why?
| | Time Factors | 4 | 2014 | 7040 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 280 | 0.060 |
Why?
| | Adult | 12 | 2020 | 40083 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 643 | 0.060 |
Why?
| | Animals | 11 | 2022 | 38068 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5319 | 0.060 |
Why?
| | Isoflavones | 1 | 2005 | 26 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1376 | 0.060 |
Why?
| | Ear, Inner | 1 | 2005 | 52 | 0.060 |
Why?
| | Young Adult | 6 | 2020 | 13992 | 0.060 |
Why?
| | Support Vector Machine | 2 | 2016 | 38 | 0.060 |
Why?
| | Mitotic Index | 2 | 2015 | 25 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 220 | 0.060 |
Why?
| | Body Fluids | 1 | 2005 | 70 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 323 | 0.050 |
Why?
| | Mice | 4 | 2022 | 18414 | 0.050 |
Why?
| | Urinary Incontinence | 1 | 2005 | 66 | 0.050 |
Why?
| | Growth | 1 | 2004 | 52 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 407 | 0.050 |
Why?
| | MAP Kinase Signaling System | 2 | 2008 | 325 | 0.050 |
Why?
| | Informed Consent | 1 | 2006 | 195 | 0.050 |
Why?
| | Disease Progression | 2 | 2018 | 2862 | 0.050 |
Why?
| | Propensity Score | 2 | 2016 | 350 | 0.050 |
Why?
| | United States | 5 | 2019 | 15584 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1511 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 1997 | 431 | 0.050 |
Why?
| | Receptors, Nicotinic | 1 | 2005 | 344 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2019 | 2542 | 0.050 |
Why?
| | Mass Screening | 2 | 2015 | 1336 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 922 | 0.050 |
Why?
| | Transcriptional Regulator ERG | 1 | 2022 | 16 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2004 | 195 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2195 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1985 | 0.040 |
Why?
| | Rats, Wistar | 3 | 1997 | 454 | 0.040 |
Why?
| | Rats | 6 | 2005 | 5611 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 357 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 130 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1136 | 0.040 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 11 | 0.040 |
Why?
| | Shc Signaling Adaptor Proteins | 2 | 1997 | 11 | 0.040 |
Why?
| | Testosterone | 2 | 2015 | 423 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2001 | 273 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2001 | 122 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 214 | 0.040 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1285 | 0.040 |
Why?
| | Fever | 1 | 2001 | 311 | 0.040 |
Why?
| | Adolescent | 5 | 2022 | 22520 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 222 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2001 | 302 | 0.040 |
Why?
| | Reperfusion | 2 | 1996 | 46 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 341 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2019 | 23 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2882 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 688 | 0.040 |
Why?
| | Geography | 1 | 2019 | 202 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2023 | 16781 | 0.040 |
Why?
| | Receptor, Notch1 | 1 | 2019 | 65 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 18 | 0.040 |
Why?
| | Zinc | 1 | 2022 | 301 | 0.040 |
Why?
| | Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 54 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 79 | 0.030 |
Why?
| | Enzyme Activation | 4 | 2008 | 790 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2001 | 453 | 0.030 |
Why?
| | Kallikreins | 1 | 2018 | 26 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 116 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 1997 | 32 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1997 | 89 | 0.030 |
Why?
| | Quality of Life | 2 | 2013 | 3082 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2022 | 752 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2005 | 4183 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 1997 | 75 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 136 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 48 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 974 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 565 | 0.030 |
Why?
| | Phosphorylation | 4 | 2008 | 1781 | 0.030 |
Why?
| | Phenotype | 3 | 2010 | 3209 | 0.030 |
Why?
| | Protein Kinase C | 2 | 1994 | 253 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7915 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 773 | 0.030 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 32 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 48 | 0.030 |
Why?
| | Altitude | 1 | 2019 | 482 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 138 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2019 | 586 | 0.030 |
Why?
| | Ischemia | 2 | 1996 | 416 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1995 | 135 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 722 | 0.030 |
Why?
| | Proteins | 2 | 1997 | 1023 | 0.030 |
Why?
| | Female | 7 | 2021 | 77403 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 973 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4668 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1736 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 78 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 310 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 710 | 0.030 |
Why?
| | Needles | 1 | 2014 | 63 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 10661 | 0.020 |
Why?
| | SEER Program | 1 | 2014 | 220 | 0.020 |
Why?
| | Radiotherapy | 1 | 2014 | 206 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 90 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1995 | 422 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 372 | 0.020 |
Why?
| | Aging | 3 | 2010 | 1955 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1995 | 399 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 533 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 524 | 0.020 |
Why?
| | Child | 3 | 2022 | 22771 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1091 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 605 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 489 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 485 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 317 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 311 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 198 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2519 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 420 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1091 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 518 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5897 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2001 | 155 | 0.020 |
Why?
| | Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 58 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 35 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 636 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 569 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 1051 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2848 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1326 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2009 | 131 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 994 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 25 | 0.020 |
Why?
| | Immunoblotting | 2 | 2001 | 313 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 56 | 0.020 |
Why?
| | Tyrosine | 2 | 2001 | 229 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2013 | 687 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3803 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1223 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 140 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2009 | 155 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1362 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 211 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1839 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 373 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2854 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2200 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 168 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 637 | 0.020 |
Why?
| | Phosphotyrosine | 2 | 1996 | 40 | 0.010 |
Why?
| | Models, Animal | 1 | 2008 | 392 | 0.010 |
Why?
| | Chinchilla | 1 | 2005 | 34 | 0.010 |
Why?
| | Equol | 1 | 2005 | 5 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1403 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2005 | 162 | 0.010 |
Why?
| | Swine | 1 | 2008 | 838 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 594 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2004 | 17 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2004 | 24 | 0.010 |
Why?
| | Bicarbonates | 1 | 2004 | 45 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2013 | 1137 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1505 | 0.010 |
Why?
| | Meat | 1 | 2005 | 93 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4242 | 0.010 |
Why?
| | Meningomyelocele | 1 | 2004 | 63 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6382 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2779 | 0.010 |
Why?
| | Body Height | 1 | 2004 | 208 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1185 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 832 | 0.010 |
Why?
| | Receptor, IGF Type 1 | 1 | 2001 | 65 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10014 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 503 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11772 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2001 | 882 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2621 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2001 | 618 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 4059 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2809 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1996 | 12 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1996 | 44 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1636 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 160 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 215 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2531 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 255 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 167 | 0.010 |
Why?
| | Phosphotransferases | 1 | 1994 | 25 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1994 | 97 | 0.010 |
Why?
| | Densitometry | 1 | 1994 | 38 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 274 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 116 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 13 | 0.010 |
Why?
| | Genes, myc | 1 | 1994 | 51 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 327 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 334 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 225 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 383 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1629 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1996 | 970 | 0.010 |
Why?
| | Gene Expression | 1 | 1994 | 1505 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1994 | 1477 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1995 | 2036 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|